Canadian sports icon faces lymphoma treatment

In September, hockey fans in both Russia and Canada will honor the 40th anniversary of what was considered at the time to be the greatest and most important international hockey series ever, the so-called Summit Series of 1972 between Team Canada and the Soviet National Team. It was widely expected that the Canadians would take down Russia easily in the eight planned games, but very quickly the opposite occurred, and when the teams headed over to Russia for the second half of the series, Canada was down in the series and being booed on their own ice.

Far and away the most iconic figure to emerge from the Summit Series was a moderately known winger named Paul Henderson. To that time, Henderson had had a good career in the NHL and was deserving of his spot on the team but few expected a whole lot from him. Surely nobody expected Henderson to score the series clinching goal for Team Canada, a goal that would become known as the Goal of the Century in Canada and retain that title to this day.

As Henderson prepares for the celebrations in September, he will also be preparing for anti-cancer treatment, as Canada's hero has been diagnosed with the indolent lymphoma subtype lymphocytic lymphoma chronic leukemia, and has been informed that he will likely require six months of chemotherapy treatment soon.

Henderson, who currently raises money for cancer charities such as Cops for Cancer, has every intention of making it to the 40th celebrations.

"Cancer is cancer," he told the Globe and Mail. "I’ve got a great life if I can just stay alive."

Source: Globe and Mail

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap